Lu anti-medical cephalosporatin capsules are evaluated by consistency.

Cephalosporadine capsules belong to cephalosporins and are divided into four generations according to their antibacterial spectrum, antibacterial activity, stability of beta-lactamase and kidney toxicity.
cephalospora is the first generation of cephalosporins, this product by inhibiting the synthesis of cell walls, so that the cell contents expand to rupture and dissolve, so as to achieve sterilization, the gram-positive bacteria (including penicillin-resistant Staphylococcus aureus) is quite effective, the stability of the gram-negative bacteria produced by beta-endamide enzyme is poor.
is suitable for acute pharyngitis, tonsillitis, otitis media, bronchitis and pneumonia and other respiratory infections, urinary tract infections and skin soft tissue infections.
this product is an oral preparation and should not be used for serious infection.
january-September 2019, domestic sales of cephalosporadin capsules were about RMB326 million, while sales revenue of Lu AntiPharmaceutical Products was RMB82,316.2 million.
currently a total of 241 cephalosporadin capsules production approval.
As of the date of this announcement, a total of 6 manufacturers (Shandong Xinhua Pharmaceutical Co., Ltd. (0.25g), Sino-American Shanghai Shiguibao Pharmaceutical Co., Ltd. (0.25g), Yangzijiang Pharmaceutical Group Co., Ltd. (0.25g), Shandong Luoxin Pharmaceutical Group Co., Ltd. (0.25g), Guangdong South China Pharmaceutical Group Co., Ltd. (0.25g), Shandong Lu Antipharmaceutical Co., Ltd. (0.25g) have been approved by the State Drug Regulatory Regulatory Administration.
the drug to carry out consistency evaluation work, Lu anti-drug cumulative research and development investment of about 8 million yuan (unaudited).
Source: Lu Anti-Pharmaceutical Bulletin Finishing: Blue Blue.